Radiation jolt may wake up fading immunotherapy
NCT ID NCT06363773
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether precise, high-dose radiation (stereotactic radiotherapy) can restore the effectiveness of anti-PD1 immunotherapy in patients with metastatic solid tumors. Participants are those who initially responded well to immunotherapy for at least 6 months but then saw their cancer progress. The radiation is given in three short sessions to one tumor, with the hope that it triggers an 'abscopal effect'—shrinking not only the treated tumor but also other distant metastases. The study enrolls 35 patients and measures tumor response at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- stereotactic radiotherapy
- What this could lead to
- If successful, this approach could offer a way to re-sensitize tumors to immunotherapy, potentially extending disease control without new drugs.
- What could go wrong
- This is a very small, early pilot study (35 patients) with no control group. The abscopal effect is rare and unpredictable, so results may not be generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 35 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, 18 years of age or older, 2. Patient with a metastatic solid tumor, 3. Patient with at least one target lesion (for radiotherapy) together with other secondary lesions that must be measurable, 4. Measurable disease according to RECIST 1.1 and iRECIST criteria, 5. Patient undergoing anti-PD1 immunotherapy as part of standard of care treatment, 6. Disease progression with immunotherapy (progression assessed by iRECIST criteria) but having received at least 6 months of immunotherapy, 7. Performance Status (PS) of 0 or 1, 8. Patient eligible for stereotactic radiotherapy, 9. Patient affiliated to or benefiting from a social security scheme, 10. Patient having been informed of the investigation and having signed the informed consent form prior to any study-specific procedures, 11. Patient willing and able to undergo all examinations and procedures in accordance with the clinical investigation plan. Exclusion Criteria: 1. Patient having received previous radiotherapy since the start of immunotherapy, 2. Patient for whom first disease progression (pre-inclusion stage) is not confirmed secondarily (inclusion stage), 3. Patient with an active implantable medical device (e.g. pacemaker) or an active medical device worn on the body that could interact adversely with stereotactic radiotherapy treatment, 4. Patient with hematological cancer, 5. Symptomatic patient requiring a rapid change of systemic line according to the investigator's judgment, 6. Concurrent participation in another clinical trial, or patient having received an investigational product within 30 days prior to inclusion, 7. Pregnant or breast-feeding women, 8. Patient under legal protection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Clinical
RECRUITINGSoyaux, Charente, 16800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a platform trial match the right drug combo to each tumor?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can a new antibody outsmart advanced solid tumors?
- Tissue analysis may guide personalized cancer therapy